Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: Role of intranasal corticosteroids

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 821-836

  Blaiss, Michael S ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Allergic conjunctivitis; Allergic eye symptoms; Intranasal corticosteroids; Ocular allergy

Indexed keywords

AGENTS ACTING ON THE EYE; ALAVERT; ANTIHISTAMINIC AGENT; AZELASTINE; BUDESONIDE; CETIRIZINE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DESLORATADINE; EMEDASTINE; EPINASTINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; KETOROLAC; KETOROLAC TROMETAMOL; KETOTIFEN; KETOTIFEN FUMARATE; LEVOCABASTINE; LEVOCETIRIZINE; LODOXAMIDE TROMETAMOL; LORATADINE; LOTEPREDNOL ETABONATE; MOMETASONE FUROATE; NAPHAZOLINE; NEDOCROMIL SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; OPCON A; OXYMETAZOLINE; PATADAY; PEMIROLAST; PHENIRAMINE; PHENYLEPHRINE; PLACEBO; STABILIZING AGENT; TETRYZOLINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOCON A; VASOCONSTRICTOR AGENT; VERAMYST; VISINE A;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; CLINICAL TRIAL; COMPRESSION; COUGHING; DATA BASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRY NOSE; EPISTAXIS; EVALUATION; EYE ALLERGY; HAY FEVER; HEALTH CARE MANAGEMENT; HUMAN; INTERNET; MEDICAL INFORMATION; MEDLINE; NOSE ALLERGY; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PHARYNGITIS; PHYSICIAN; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; THERAPY EFFECT;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; EYE DISEASES; HISTAMINE H1 ANTAGONISTS; HUMANS; MAST CELLS; PRIMARY HEALTH CARE; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; VASOCONSTRICTOR AGENTS;

EID: 41149167153     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X253780     Document Type: Review

References (106)

1. Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999;5:485-96
2. Strachan D, Sibbald B, Weiland S, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161-76
3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2-S8
4. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology [American Academy of Allergy, Asthma, and Immunology]. Ann Allergy Asthma Immunol 1998;81:478-518
5. Singh K, Bielory L [poster 34]. Poster presented at the American College of Allergy, Asthma & Immunology. Philadelphia, PA. November 10-15, 2006
6. Allergies in America. Executive summary. Available at: www. myallergiesinamerica.com/news/overview.aspx [last accessed 29 March 2007]
7. Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66:2309-19
8. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergie rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158-62
9. Keslin MH, Jarrell CM, Gregory C. Diagnosis and treatment of allergic rhinitis: primary care in an integrated health system setting. Am J Manag Care 1999;5(Suppl):S249-S256
10. Bielory L. Role of antihistamines in ocular allergy. Am J Med 2002;113(Suppl 9A):34S-37S
11. Klein B, Schmit-Eilenberger V, Schwalbe C, et al. Assessing the impact of eye allergy symptoms using the Eye Allergy Patient Impact Questionnaire (EAPIQ). Poster presentation at Deutsche Ophthalmologische Gesellscaft. Berlin. September 23-26, 2004
12. Buchholz PM, Wlat J, Lorenz D, et al. Patient impact of allergic conjunctivitis as measured by the Eye Allergy Patient Impact Questionnaire (EAPIQ). Poster presented at the Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida. May 7, 2003
13. Van Hoecke H, Vastesaeger N, Dewulf L, et al. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006;61:705-11
14. Bousquet J, Annesi-Masesano I, Carat J, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728-32
15. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18:485-92
16. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-S334
17. Goodwin D. Management of ocular allergies. Pacific Optometry Continuing Education, 2006. Available at: www.opt.pacificu. edu/ce/catalog/16627-AS/16627- AS.html [last accessed 21 May 2007]
18. Bremond-Gignac D. The clinical spectrum of ocular allergy. Curr Allergy Asthma Rep 2002;2:321-4
19. van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-99
20. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17-33
21. Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12:233-42
22. Alexander M, Berger W, Buchholz P, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005;3:67
23. Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep 2002;2:223-30
24. Bielory L. Allergic diseases of the eye. Med Clin North Am 2006;90:129-48
25. Bonini S. Allergic conjunctivitis: the forgotten disease. Chem Immunol Allergy 2006;91:110-20
26. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-28
27. Bonini S, Bonini S, Massimo B, et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol 1990;96:869-76
28. Bonini S, Bonini S, Vecchione A, et al. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 1988;82:462-9
29. Morrow GL, Abbott RL. Conjunctivitis. American Family Physician. February 15, 1998. Available at: www.aafp.org/ afp/980215ap/morrow.html [last accessed 21 May 2007]
30. Allergy drugs. Review of Optometry. June 15, 2006. Available at: www.revoptom.com/drugguide/pdf/article6.pdf [last accessed 4 May 2007]
31. Sheppard J. Getting allergy symptoms under control. Ophthalmology Management. June 2002. Available at: www. ophthalmologymanagement.com/article. aspx?article=85402 [last accessed 4 May 2007]
32. Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58-70
33. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-53
34. Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 2003;24: 95-105
35. Indiana University School of Optometry Continuing Education. Treatment for allergic conjunctivitis. March 2007. Available at: www.opt.indiana.edu/ce/ allergy/tx/htm [last accessed 3 June 2007]
36. Dockhorn RJ, Duckett TG. Comparison of Naphcon-A and its components (naphazoline and pheniramine) in a provocative model of allergic conjunctivitis. Curr Eye Res 1994;13:319-24
37. Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451-6
38. Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc 2007;28:427-33
39. Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26: 35-47
40. Crampton JH. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double masked, placebo- and active-controlled trial. Clin Ther 2003;25:1975-87
41. Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin 2004;20:1953-8
42. Katelaris CH, Ciprandi G, Missotten L, et al., for the International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24:1561-75
43. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462-72
44. Greiner JV, Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther 2003;25: 1988-2005
45. Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 1999;228(Suppl):47-52
46. Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002;24:918-29
47. James IG, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003;19:313-20
48. Alexander M, Allegro S, Hicks A. Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Adv Ther 2000; 17:140-7
49. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):141-8
50. Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Immunol 1991;96:344-7
51. 1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest 2001;21:25-32
52. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis: Desloratadine Study Group. J Allergy Clin Immunol 2003;111:617-22
53. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612-21
54. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111: S835-S842
55. Nevius JM, Abelson MB, Welch D. The ocular drying effect of oral antihistamines (loratadine) in the normal population: an evaluation. Invest Ophthalmol Vis Sci 1999;40(Suppl): S549
56. Simons FE, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005;116:355-61
57. Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92: 294-303
58. Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307-13
59. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003;26:863-93
60. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73:382-94
61. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181-8
62. Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995;252: 455-8
63. Berlin JM, Golden SJ, Teets S, et al. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc 2000;100(Suppl):S8-S13
64. Baroody FM, Foster K, Markarian A, et al. Nasal ocular reflexes occur after nasal challenge with allergen. J Allergy Clin Immunol 2007;119:S162
65. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331-7
66. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-7
67. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999;104:S144-S149
68. Gradman J, Caldwell M, Wolthers O, et al. Knemometric assessment of short-term lower-leg growth in children with allergic rhinitis (AR) treated with fluticasone furoate (FF) nasal spray. J Allergy Clin Immunol 2007;119:S304
69. Rhinocort Aqua (budesonide) prescribing information. Wilmington (DE): Astra Zeneca LP; January 2005
70. Nasarel (flunisolide) nasal spray prescribing information. Available at: www.drugs.com/pro/nasarel/html [last accessed 31 May 2007]
71. Nasonex (mometasone furoate monohydrate) nasal spray prescribing information. Kenilworth (NJ): Schering Corporation; September 2005
72. Nasacort AQ (triamcinolone acetonide) nasal spray prescribing information. Bridgewater (NJ): sanofi-aventis US, LLC; September 2006
73. Flonase (fluticasone propionate) nasal spray prescribing information. Research Triangle Park (NC): GlaxoSmithKline; March 2004
74. Veramyst (fluticasone furoate) nasal spray prescribing information. Research Triangle Park (NC): GlaxoSmithKline; April 2007
75. Tinkelman D, Falliers C, Gross G, et al. Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Ann Allergy 1990;64:234-40
76. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;17:252-63
77. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586-91
78. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119: 1430-7
79. Hebert J, Gates D, Danzig M. Mometasone furoate nasal spray improves total ocular symptom score in subjects with seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119(Suppl 1):S61
80. Anolik R, Pearlman D, Danzig M, Gates D. Mometasone furoate nasal spray improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescent subjects. J Allergy Clin Immunol 2007;119(Suppl 1):S61
81. Bielory L, Danzig MR, Gates D. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Asthma Allergy Immunol [in press]
82. Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis. Allergy Clin Immunol Int 2007;19:50-3
83. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216-25
84. Ratner PH, Wingerzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006;118: 1142-8
85. Anolik R, Danzig M, Gates D. Efficacy of intranasal mometasone furoate in alleviating the ocular symptoms of seasonal allergic rhinitis. Poster presented at: XXVI Congress of the European Academy of Allergology and Clinical Immunology; June 9-13, 2007; Göteborg, Sweden
86. 1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J 1998;317:1624-9
87. Robinson AC, Cherry JR, Daly S. Double-blind cross-over trial comparing beclomethasone dipropionate and terfenadine in perennial rhinitis. Clin Exp Allergy 1989;19:569-73
88. Brooks CD, Francom SF, Peel BG, et al. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinol 1996;10:193-9
89. Bronsky EA, Dockhorn RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-21
90. Bunnag C, Jareoncharsri P, Wong EC. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 1992;47: 313-7
91. Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995;17: 479-92
92. Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97:749-55
93. Darnell R, Pecoud A, Richards DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 1994;24:1144-50
94. Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994;73:497-502
95. Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989;83:627-33
96. Wood SF. Oral antihistamine or nasal steroid in hay fever: a double-blind double-dummy comparative study of once daily oral astemizole vs. twice daily nasal beclomethasone dipropionate. Clin Allergy 1986;16:195-201
97. Beswick KBJ, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985;9:560-7
98. Gawchik SM, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis. Am J Manag Care 1997;3:1052-8
99. Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000;84:533-8
100. 1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479-84
101. Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236-41
102. Ortolani C, Foresi A, DiLorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis [FLNCO2 Italian Study Group]. Allergy 1999;54:1173-80
103. Svensson C, Andersson M, Greiff L, et al. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy 1998;53:367-74
104. Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003;25: 2245-67
105. Simpson K, Blair J. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-21
106. Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002;24: 1161-74